Table 2.
Patients’ characteristics in the training and validation datasets.
| Clinical phenotypes | ||||||
|---|---|---|---|---|---|---|
| Training dataset (N = 6322) | Validation dataset (N = 3068) | |||||
| RRMS | SPMS | PPMS | RRMS | SPMS | PPMS | |
| Percentage of populationa | 46% (2884) | 29% (1837) | 25% (1601) | 49% (1522) | 28% (845) | 23% (701) |
| Age at study entryb | 37.44 ± 9.2 | 49.41 ± 8.09 | 49.20 ± 8.41 | 36.53 ± 9.69 | 51.95 ± 7.92 | 44.58 ± 8.02 |
| Female (%) | 68% | 65% | 50% | 69% | 67% | 50% |
| EDSSc | 2.5 (1.5–3.5) | 6 (5–6.5) | 4.5 (4–6) | 2.5 (1.5–4.5) | 6 (5–7) | 4.5 (2–7) |
| Disease duration (SD)b | 4.62 ± 5.46 | 14.46 ± 8.77 | 4.47 ± 4.56 | 3.24 ± 4.42 | 17.52 ± 9.38 | 2.78 ± 3.1 |
| Progression duration (SD)b | — | 5.24 ± 4.04 | — | — | 6.38 ± 5.2 | — |
aThe total percentages may not add up to 100% because of rounding.
bAverage years with standard deviation in parentheses.
cMedian EDSS with interquartile range in parentheses.
Age, disease duration, EDSS and progression duration are calculated at the study entry.
NS non-significant, SD standard deviation, SE standard error of mean, NAWM normal-appearing white matter, EDSS expanded disability status scale, RRMS relapsing remitting multiple sclerosis, SPMS secondary progressive multiple sclerosis, PPMS primary progressive multiple sclerosis.